Gilead Sciences (GILD) Profit After Tax Growth (3y) (2012 - 2026)
Gilead Sciences (GILD) Profit After Tax Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 0.97% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 21.28% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 39.29% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 12.02% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 19.41% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 19.87% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -129.22% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -37.78% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -54.33% |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -34.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -129.22% |
| Mar 31, 2026 | 26.01% |
| Dec 31, 2025 | 10.00% |
| Sep 30, 2025 | 19.55% |
| Jun 30, 2025 | 19.66% |
| Mar 31, 2025 | 310.57% |
| Dec 31, 2024 | 70.77% |
| Sep 30, 2024 | -21.52% |
| Jun 30, 2024 | 1.98% |
| Mar 31, 2024 | -64.13% |
| Dec 31, 2023 | -2.97% |
| Sep 30, 2023 | 82.05% |
| Jun 30, 2023 | 32.20% |
| Mar 31, 2023 | -13.08% |
| Dec 31, 2022 | -15.20% |
| Sep 30, 2022 | 52.31% |
| Jun 30, 2022 | -15.26% |
| Mar 31, 2022 | -78.71% |
| Dec 31, 2021 | 392.33% |
| Sep 30, 2021 | 7.29% |